Mutations in Ebf1, Pax5 and Ikaros, three transcription factors that form an interrelated gene network required to initiate B cell development, are frequently mutated in progenitor B-ALL. Likewise, the transcription factor STAT5 is frequently activated in B-ALL. Importantly, mutations in the Ebf1/Pax5/Ikaros network, most notably for Ikaros, have been shown to correlate with poor outcome in human ALL;we and others have observed a similar correlation between STAT5 activation in ALL and poor prognosis. However, whether mutations in the Ebf1Pax5/Ikaros network, or STAT5 activation, drive transformation or are merely passengers in this process remains unclear. We recently obtained an important insight to this question by crossing mice expressing a constitutively active form of STAT5b (called Stat5b-CA) to mice heterozygous for Ebf1 or Pax5. Stat5b-CA mice develop ALL with very low penetrance (1-2%) while Pax5 and Ebf1 mice show no predisposition to develop ALL. In contrast, 100% of Stat5b-CA x Pax5 and Stat5b-CA x Ebf1 mice developed ALL with an average age of onset of 55 and 108 days after birth, respectively. Importantly, Stat5b-CA x Ebf1 and Stat5b-CA x Pax5 leukemias did not lose the other allele of either Ebf1 or Pax5, respectively. Our hypothesis is that genes that make up the Ebf1/Pax5/Ikaros network do not act as classical tumor suppressor genes but rather function as part of an integrated tumor suppressor gene network. In this model loss of any two alleles of any of the genes in the network, as opposed to both alleles of the same gene is sufficient for loss of tumor suppressor function. We further propose that STAT5 activation is needed to pair with loss-of-function mutations in the Ebf1/Pax5/Ikaros network to initiate transformation. In this grant application, we will test these hypotheses using a Sleeping beauty transposon-based mutagenesis strategy. In addition, we will test whether defects in the Ebf1/Pax5/Ikaros network in human ALL correlate with increased STAT5 signaling. Finally, we will also use the Sleeping Beauty genetic screen to identify other genes that cooperate with defects in the Ebf1/Pax5/Ikaros network and STAT5 activation to initiate and promote progenitor B-ALL. These studies should provide important insights into the role that STAT5 and the Ebf1/Pax5/Ikaros network play in causing B-ALL as well as identify additional genes that play key roles in the process of transformation.
Mutations in a network of genes involving particularly Ebf1, Pax5 and Ikaros are frequently found in acute lymphoblastic leukemia (ALL). In this grant application we propose studies that will identify the factors that cooperate with defects in these three genes to initiate leukemia. We also hope to identify useful biomarkers that may allow for identification of high versus low risk ALL and test whether therapies directed against specific targets identified in our study may be useful for treating ALL.
|Katerndahl, Casey D S; Heltemes-Harris, Lynn M; Willette, Mark J L et al. (2017) Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol 18:694-704|
|Heltemes-Harris, L M; Larson, J D; Starr, T K et al. (2016) Sleeping Beauty transposon screen identifies signaling modules that cooperate with STAT5 activation to induce B-cell acute lymphoblastic leukemia. Oncogene 35:3454-64|
|Manlove, Luke S; Schenkel, Jason M; Manlove, Kezia R et al. (2016) Heterologous Vaccination and Checkpoint Blockade Synergize To Induce Antileukemia Immunity. J Immunol 196:4793-804|
|Manlove, Luke S; Berquam-Vrieze, Katherine E; Pauken, Kristen E et al. (2015) Adaptive Immunity to Leukemia Is Inhibited by Cross-Reactive Induced Regulatory T Cells. J Immunol 195:4028-37|
|Mahmud, Shawn A; Manlove, Luke S; Schmitz, Heather M et al. (2014) Costimulation via the tumor-necrosis factor receptor superfamily couples TCR signal strength to the thymic differentiation of regulatory T cells. Nat Immunol 15:473-81|
|Liu, Grace J; Cimmino, Luisa; Jude, Julian G et al. (2014) Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia. Genes Dev 28:1337-50|
|Mahmud, Shawn A; Manlove, Luke S; Farrar, Michael A (2013) Interleukin-2 and STAT5 in regulatory T cell development and function. JAKSTAT 2:e23154|
|Heltemes-Harris, Lynn M; Farrar, Michael A (2012) The role of STAT5 in lymphocyte development and transformation. Curr Opin Immunol 24:146-52|